We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+28.34%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$15.2B
AUM Growth
+$1.87B
Cap. Flow
+$90.5M
Cap. Flow %
0.6%
Top 10 Hldgs %
84.66%
Holding
125
New
12
Increased
14
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$50.5M
2
AMRN
Amarin Corp
AMRN
+$43.1M
3
INSM icon
Insmed
INSM
+$26M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$22.4M
2
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$20.8M
3
HALO icon
Halozyme
HALO
+$14.6M
4
EXEL icon
Exelixis
EXEL
+$11M
5
XNCR icon
Xencor
XNCR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.42%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
76
DELISTED
Adamas Pharmaceuticals
ADMS
$3.46M 0.02%
172,630
– –
ARAV
77
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.4M 0.02%
404,385
– –
RARX
78
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.22M 0.02%
177,952
– –
LJPC
79
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.11M 0.02%
154,675
– –
TRIL
80
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.93M 0.02%
505,262
-6,501
-1% -$36.6K
KRYS icon
81
Krystal Biotech
KRYS
$10.3B
$2.02M 0.01%
114,674
-85,326
-43% -$1.43M
AQST icon
82
Aquestive Therapeutics
AQST
$585M
$1.74M 0.01%
+99,600
New +$1.64M
RCUS icon
83
Arcus Biosciences
RCUS
$3.86B
$1.69M 0.01%
121,534
– –
INFI
84
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.57M 0.01%
580,400
– –
MTEM
85
DELISTED
Molecular Templates, Inc.
MTEM
$1.37M 0.01%
16,949
+12,122
+251% +$929K
OVID icon
86
Ovid Therapeutics
OVID
$547M
$1.26M 0.01%
222,139
-25,594
-10% -$194K
VIRX
87
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.11M 0.01%
15,905
– –
DVAX
88
DELISTED
Dynavax Technologies
DVAX
$930K 0.01%
75,000
– –
CNST
89
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$897K 0.01%
+133,333
New +$1.27M
AFMD
90
DELISTED
Affimed
AFMD
$870K 0.01%
20,000
-20,000
-50% -$567K
TARA icon
91
Protara Therapeutics
TARA
$228M
$582K ﹤0.01%
7,465
– –
AIXC
92
AIxCrypto Holdings Inc
AIXC
$22.7M
$521K ﹤0.01%
22
– –
FLGT icon
93
Fulgent Genetics
FLGT
$548M
$491K ﹤0.01%
125,000
– –
ABUS icon
94
Arbutus Biopharma
ABUS
$1.03B
– –
-180,582
Closed -$1.32M
ADAP
95
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-100,000
Closed -$1.19M
AKTX
96
Akari Therapeutics
AKTX
$15.3M
– –
-73
Closed -$115K
CARM
97
DELISTED
Carisma Therapeutics
CARM
– –
-131,221
Closed -$5.12M
CLLS
98
Cellectis
CLLS
$342M
– –
-50,000
Closed -$1.42M
CRBP icon
99
Corbus Pharmaceuticals
CRBP
$201M
– –
-8,248
Closed -$1.25M
BGMSP
100
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
– –
-13,253
Closed -$89K
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2018 Portfolio in Review

As of Q3 2018, Julian Baker held 125 positions worth $15.2B, up 14% from $13.3B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Julian Baker's Q3 2018 filing shows 12 new, 14 increased, 21 reduced and 27 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M. The largest sale was bluebird bio, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M.
  • Julian Baker added most to Amarin Corp in Q3 2018, an estimated $43.1M increase.
  • Julian Baker's biggest Q3 2018 reduction was bluebird bio, cutting an estimated $22.4M.
  • Julian Baker fully exited Exelixis in Q3 2018, selling an estimated $11M.
  • Julian Baker's ten largest holdings make up 85% of its $15.2B portfolio in Q3 2018.
  • Julian Baker opened 12 new positions and closed 27 in Q3 2018.
  • Julian Baker's portfolio value rose 14% quarter-over-quarter to $15.2B.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.